Tags : Four-Year Collaboration

Biotech

Gilead Sciences and Second Genome Signs a Four-Year Collaboration to

Shots: Second Genome will receive $38M as upfront, up to $300M milestones for each of five target discovery programs and royalties for approved therapies. Additionally, it will receive milestones for each validated biomarker delivered under the collaboration The collaboration will deploy Second Genome’s Microbiome Analytics Platform to identify biomarkers associated with clinical response in up […]Read More